Company: GHRS
Filing Date: 2025-02-27
Form Type: 20-F
Source: 0001140361-25-006175
Chunk: 126

Company: GH Research PLC
Filing Date: 2025-02-27
Form: 20-F
Item: Item 16
Chunk 126
---
 regulatory filings.
 
Pre-Approval Policies and Procedures
 
In accordance with the requirements of the Sarbanes-Oxley Act and rules issued by the SEC, our audit committee reviews and pre-approves all audit and permitted non-audit services performed by our independent registered public accounting firm. The procedures require that all proposed future engagements of our independent registered public accounting firm for audit and permitted non-audit work are submitted to our audit committee for approval prior to the beginning of any such service. In accordance with this policy, all services performed by, and all fees paid to PwC entities after our initial public offering were approved by our audit committee, following its formation.
 
D.
Exemptions From The Listing Standards For Audit Committees
 
None.
 
E.
Purchases Of Equity Securities By The Issuer And Affiliated Purchasers
 
During the year ended December 31, 2024, no purchases of our equity securities were made by or on behalf of GH Research PLC or any “affiliated purchaser” as such term is defined in Rule 10b-18 under the Exchange Act.
F.
Change In Registrant’s Certifying Accountant
 
None.
 
G.
Corporate Governance
 
As a “foreign private issuer,” as defined by the SEC, we are permitted, consistent with Nasdaq Stock Market Rule 5615(a)(3), to follow home country corporate governance practices, instead of certain corporate governance standards required by Nasdaq for U.S. companies. Accordingly, we follow Irish corporate governance rules in lieu of certain of Nasdaq’s corporate governance requirements. A foreign private issuer that elects to follow a home country practice instead of any of any such Nasdaq requirements must submit to Nasdaq, in advance, a written statement from an independent counsel in such issuer’s home country certifying that the issuer’s practices are not prohibited by the home country’s laws. We provided Nasdaq with such a letter of non-compliance with respect to:

•   The Rule requiring maintaining a majority of independent directors (Rule 5605(b)(1)). Although we currently maintain a majority of independent directors, we may follow Irish law and practice in the future, under which we are not
                                                                                          required to appoint a majority of independent directors.                                                                                      
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

•   The Rule requiring that our independent directors have regularly scheduled meetings at which only independent directors are present (Rule 5605(b)(2)). Instead, we follow Irish law according to which independent directors are not
                                                                                                    required to hold executive sessions.                                                                                                
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------